Alkermes Continues to Execute
Alkermes (NASDAQ: ALKS), a biopharmaceutical company focused on diseases of the central nervous system, released its second-quarter earnings results on Thursday, July 27. The report showed that revenue once again grew at double-digit rates thanks to increased demand for Vivitrol and Aristada. In addition, the company continues to make steady progress at moving its late-stage product candidates one step closer to the finish line.
Image source: Getty images.
Data source: Alkermes. GAAP = generally accepted accounting principles. EPS = earnings per share. NM = not meaningful due to negative figures.
Source: Fool.com
Alkermes plc Stock
€25.40
-0.780%
With 17 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 35 € there is a positive potential of 37.8% for Alkermes plc compared to the current price of 25.4 €.
